Microparticles and Applications in Assays and Endpoints

Biomarkers, Life Sciences,
  • October 29, 2013 | 10am BST (UK) / 11am CEST (EU-Central) / 5am EDT (NA)
  • 0 min

Recording not available for this webinar

Microparticles are 100 – 1000 nm subcellular bodies released during apoptosis, cell injury, or cellular activation. Serum, plasma, synovial fluid, CSF, and other biofluid-derived circulating microparticles have been increasingly suggested as meaningful matrices for biomarker assay development.

Originating from a variety of cells including endothelium, platelets, and synoviocytes, microparticles maintain features of their parent cells including surface elements, some intracellular organelles and miRNA. Recent publications have described microparticle quantity and quality as indicators of cardiovascular/myocardial infarction risk, metastatic tumor status, inflammatory status and endothelial dysfunction.


The Covance Biomarker Center of Excellence has seen an increasing number of requests for microparticle quantitation and/or characterization in drug discovery and development studies. However, there remains much to learn about this material and its use as a matrix for routine biomarker measurement.

This webinar will focus on Covance’s experience in standardization of methods for microparticle isolation from preclinical and clinical samples, as well as recent findings from microparticle analyses in disease models of oncology and cardiovascular/metabolic disease. Finally, opportunities for the use of microparticles as translational biomarkers spanning the drug discovery to drug development interface will be discussed.


Katherine T. Landschulz, PhD, Manager, Biomarker Center of Excellence, Covance

Dr. Landschulz received her PhD in Human Genetics/Biology from Johns Hopkins University, Baltimore, Maryland and has over 15 years of experience working in Pharmaceutical research and development. She has lead drug discovery, genomic and proteomic biomarker discovery, translational medicine and pharmacogenomic efforts. Dr. Landschulz joined Covance in 2010 as Principal Scientist/Cardiovascular, Metabolic Disease Therapeutic Area lead and and is currently Manager of the Biomarker Center of Excellence Assay Production team. She has been exploring the use of microparticles as biomarkers in models of oncology, cardiovascular disease and diabetes for the past 3 years.

Who Should Attend?

BioPharma decision makers working in biomarker development

Xtalks Partners


Covance, with headquarters in Princeton, New Jersey, is one of the world’s largest and most comprehensive drug development services companies, with annual revenues greater than $2 billion and more than 11,000 employees in more than 60 countries. Covance has the people, processes, client service, and global resource capabilities to respond to biotechnology and Pharmaceutical clients’ toughest drug development challenges.

Media Partners

Related Webinars

Sign Up To Register for this Webinar

Interested in this webinar? Signup to learn more and register for upcoming webinars or recorded webinars.

Sign Up